Outset Medical Inc. (OM) Misses Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Outset Medical Inc. (OM) to Resume Trading at 10:30 a.m.
August 1, 2022 10:15 AM EDTOutset Medical Inc. (NASDAQ: OM) to Resume Trading at 10:30 a.m.
Outset Medical (OM) Resumes Shipment of Tablo Systems for Home Use, Reports Second Quarter 2022 Financial Results and Provides 2022 Guidance
August 1, 2022 10:03 AM EDTOutset Medical, Inc. (Nasdaq: OM) (Outset or the Company), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced clearance by the Food and Drug Administration of its previously disclosed 510(k) submission and resumption of Tablo® Hemodialysis System shipments for home use.
The Company also reported financial results for the second quarter ended June 30, 2022 and provided financial guidance for 2022. Revenue for the second quarter totaled $25.1 million, in line with guidance provided on June 13, 2022. Gross margin for the second quarter was 15.1%, compared to 4.2% in the second... More
Outset Medical Inc. (OM) Halted, News Pending
August 1, 2022 9:37 AM EDTOutset Medical Inc. (NASDAQ: OM) Halted, News Pending
... MoreCowen Reiterates Outperform Rating on Outset Medical Inc. (OM), Comments on FDA Clearance
August 1, 2022 8:58 AM EDTCowen analyst Joshua Jennings reiterated an Outperform rating and $33.00 price target on Outset Medical Inc. (NASDAQ: OM).
The analyst comments "OM Has Received a New 510(k) Clearance for the Tablo Hemodialysis System. In a decision dated July 29, 2022, the FDA cleared a new 510(k)... More
Stifel on Outset Medical Inc. (OM): 'At Last, A Big Sigh of Relief As FDA Terms Tablo Catch-Up Filing As “Substantially-Equivalent”'
August 1, 2022 8:57 AM EDTStifel analyst Rick Wise reiterated a Buy rating and $24.00 price target on Outset Medical Inc. (NASDAQ: OM).
The analyst comments "Last Friday, Outset received a positive FDA update on its Tablo catch-up 510K filing, with the agency providing a substantially-equivalent decision on the filing.... More
